Skip to main content
. 2022 Sep 5;22:952. doi: 10.1186/s12885-022-10045-0

Fig. 2.

Fig. 2

Clinical outcomes associated with second-line sintilimab plus docetaxel therapy. Waterfall plot (A) and swimmers plot (B) illustrating the best change in tumor size and duration of response of each of the 30 patients who received sintilimab plus docetaxel as second-line therapy. Clinical details and the PD-L1 tumor proportion score (TPS) subgroup of each patient were indicated by different colors